New treatment for patients with relapsed/refractory multiple myeloma

For patients with multiple myeloma resistant to available therapies, an experimental drug studied by an international, multi-center team led by Winship’s Sagar Lonial, MD, displayed a 31 percent overall response rate and is thus a significant new option.

Learn about multiple myeloma care at Winship, visit https://winshipcancer.emory.edu/multiple-myeloma.